Inovio Pharmaceuticals Inc (INO)

[Kristallweizen]

"This new preclinical data further validates the ability of Inovio's vaccines to induce powerful antigen-specific immune responses," said Dr. J. Joseph Kim, Inovio's president and CEO, in a release. "In the past year, we have demonstrated best-in-class clinical immunogenicity data from our DNA vaccines for cervical cancer and HIV in Phase I studies. Collectively, these clinical and preclinical studies further substantiate our product development efforts in these important disease areas."

The company plans to conduct two Phase I trials for the clade C vaccine using human patients in the U.S. and Africa, thanks in part to a $25 million NIAID contract.

Read more: Inovio posts positive precinical HIV vax results - FierceVaccines www.fiercevaccines.com/story/inovio-posts-positive-precinical-hiv-vax-results/2011-07-06#ixzz1RMHe7QD3
Subscribe: http://www.fiercevaccines.com/signup?sourceform=Viral-Tynt-FierceVaccines-FierceVaccines